Viropharma Incorporated: Strategic Corporate Assessment

Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile

Publication Date	August 2008
Publisher	Datamonitor
Product Type	Report
Pages	48
ISBN Number	not applicable
Product Code	DAT08224

Price

£265.00
approximately: $387 | €290

PDF

PRINT £315 ($460 | €345)

Order above formats by FAX

Summary

Introduction

ViroPharma focuses on the development and commercialization of medicines to address diseases associated with hospital settings, transplant medicine and gastroenterology.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company's total revenues increased at a CAGR of 134% during 2002-2006, from $6 million to $167 million. The company's biggest contributor to revenue growth during 2002-2006 was product sales of Vancocin.

The company's biggest contributor to sales growth out to 2010 will continue to be Vancocin.However, revenues from Vancocin are expected to increase only at a CAGR of 1%, from $167 million in 2006 to $175 million in 2010. This could be attributable to generic competition for Vancocin, whose patent expired in 1996.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Products & Services
Marketed Products
Pipeline Products
Historical Product Sales
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Sales
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview
APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer
TABLE OF FIGURES
- Figure1: ViroPharma- Operating Revenue/Cost Analysis, 200307 ($ Mn)
- Figure2: ViroPharma- Key Strategic Products Revenues, 200711 ($ Mn)
TABLE OF TABLES
- Table 1: ViroPharma- Key Facts
- Table 2: ViroPharma- Year-End Share Price and Market Capitalization, 200307 ($)
- Table 3: ViroPharma- Key Events Impacting Share Price Performance, 200307
- Table 4: ViroPharma- Operating Revenue/Cost Analysis, 200307 ($ Mn)
- Table 5: ViroPharma- Operating Cost Ratio Analysis, 200307 (% of total revenues)
- Table 6: ViroPharma- Balance Sheet, 200307 ($ Mn)
- Table 7: ViroPharma- Cash Flow, 200307 ($ Mn)
- Table 8: ViroPharma- Marketed Products
- Table 9: ViroPharma- In-house Pipeline Products
- Table 10: ViroPharma- Historical Product Sales, 200307 ($ Mn)
- Table 11: ViroPharma- Forecast Sales, 200711 ($ Mn)
- Table 12: ViroPharma- Key Competitors
- Table 13: ViroPharma- Key Suppliers
- Table 14: ViroPharma- Key Clients
- Table 15: ViroPharma- Key Shareholders
- Table 16: ViroPharma- SWOT Analysis Summary
- Table 17: ViroPharma Value Chain Analysis
- Table 18: ViroPharma- Scorecard
- Table 19: ViroPharma- Key Employees
- Table 20: ViroPharma - Financial and Operational Overview